Summary
A definitive report on the current status and future prospects of Central Clinical Pathology Laboratories, Central ECG Analysis Laboratories and Central Bio-imaging Laboratories.
The Central and Core Laboratories market is now worth more than $1.5 billion a year and is vital to the successful development of new drugs. It is a truly global business dominated by major players.
Choosing the right Central Laboratory and handling the relationship effectively is vital to the successful management of clinical trials, as is the complex business of getting samples from the patient to the laboratory.
In a publishing breakthrough this 250 page report - updated October 2007 - gives comprehensive cover the Central Laboratories market, the major companies involved, the processes, including testing and logistics and the future challenges for the market. It is a vital resource for anyone involved in drug development, clinical trials, the central labs market and logistics.
Contents include:
- Overview of capabilities and facilities
- Role of Central Labs in clinical trials
- History of the Central Labs business
- Contract Considerations
- Review of the current market
- Logistics
- Review of leading companies
- Regulatory and QA issues
- ECG laboratories
- Imaging laboratories
- Future trends and challenges
The comprehensively-referenced report is published by Biopharm Knowledge Publishing, Part of the Technomark Group and is edited by Dr Graham Hughes, one of the leading experts on pharmaceutical outsourcing and one of the founders of Technomark. Contributors include:
- Dr Graham Hughes
- Richard Barrett
- David J. Cocker
- Eileen Daniel
- Dr Colin Miller
- Tim Stiles
This 250 page report provides a full picture of a fast-growing industry now worth more than $1 billion and vital to the success of drug development. It also gives a complete guide to managing the outsourcing and logistics process.
|
